Successfully implementing the product-specific Q-code for the company’s Cimerli (ranibizumab-eqrn) biosimilar to Genentech’s Lucentis from 1 April saw sales of Coherus BioSciences’ product more than quadruple in the second quarter, from $6.2m to $26.7m, realizing an anticipated uptick for the company.
Meanwhile, Cimerli’s market share amongst the ranibizumab products in the market also more than quadrupled from 4.1% to 17% in...